Jefferies Assumes Myriad Genetics at Underperform, Lowers Price Target of $20
Portfolio Pulse from Benzinga Newsdesk
Jefferies analyst Tycho Peterson has assumed coverage of Myriad Genetics (NASDAQ:MYGN) with an Underperform rating and has lowered the price target to $20.
June 03, 2024 | 1:11 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Jefferies analyst Tycho Peterson has assumed coverage of Myriad Genetics with an Underperform rating and has lowered the price target to $20.
The Underperform rating and lowered price target from a reputable analyst at Jefferies is likely to negatively impact investor sentiment and could lead to a short-term decline in Myriad Genetics' stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100